Latest News about INCY
Recent news which mentions INCY
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
September 18, 2023
From Benzinga
Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share
August 01, 2023
Tickers
INCY
From Benzinga
Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings
July 25, 2023
From Benzinga
From Benzinga
From Benzinga
'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla
July 19, 2023
From Benzinga
From Benzinga
2 Low-Priced Stocks That Could Make You Richer
June 26, 2023
From Motley Fool
From MarketWatch
From Benzinga
From Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
From InvestorPlace
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target
April 10, 2023
Tickers
INCY
From Benzinga
From Benzinga
From Benzinga
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
March 24, 2023
Tickers
INCY
From Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
From Benzinga
From InvestorPlace
Why Shares of MacroGenics Climbed Thursday
March 16, 2023
From Motley Fool
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
March 06, 2023
Tickers
INCY
From Benzinga
Why the stock market rally can keep going, says Wall Street strategist who only recently warned of a death zone.
March 06, 2023
From MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.